GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Magnasense AB (FRA:52Q) » Definitions » Debt-to-Revenue

Magnasense AB (FRA:52Q) Debt-to-Revenue : N/A (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Magnasense AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Magnasense AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.47 Mil. Magnasense AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €3.36 Mil. Magnasense AB's annualized Revenue for the quarter that ended in Dec. 2024 was €0.00 Mil.


Magnasense AB Debt-to-Revenue Historical Data

The historical data trend for Magnasense AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Magnasense AB Debt-to-Revenue Chart

Magnasense AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial N/A 0.10 4.20 365.63 N/A

Magnasense AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Magnasense AB's Debt-to-Revenue

For the Medical Devices subindustry, Magnasense AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Magnasense AB's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Magnasense AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Magnasense AB's Debt-to-Revenue falls into.


;
;

Magnasense AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Magnasense AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.47 + 3.356) / N/A
=N/A

Magnasense AB's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.47 + 3.356) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Magnasense AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Magnasense AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Magnasense AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, SE-223 63
AegirBio AB is a Swedish diagnostic company, specializes in developing a home testing platform for oral health, therapeutic drug monitoring and infectious diseases. The current product line up includes the Veritope technology, featuring intact natalizumab in MS, along with the MagniaReader designed for both research and veterinary applications.

Magnasense AB Headlines

No Headlines